Letter to the Editor
Colistin-associated Acute Renal Failure: Revisited
Abstract
Sodium colistimethate (colistin) is a parenterally administered polymyxin antibiotic that acts by disrupting bacterial cell membranes. It has been primarily used in the treatment of life-threatening infections caused by multidrug-resistant Gram-negative bacteria, particularlyPseudomonas aeruginosa. The drug has a very narrow therapeutic ratio, with neurotoxicity and nephrotoxicity being the limiting factors. Nephrotoxicity has been reported in 20% of 317 courses of colistin therapy.1 An additional 14 cases of colistin-associated acute renal failure have also been reported before 1974. The risk of nephrotoxicity increases in the setting of preexisting renal dysfunction2,3 and with increasing doses.4 Serum levels and toxicity appear to be a function of the glomerular filtration rate.3This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.